Genetic redirection of T cells for the treatment of pancreatic cancer

AI Ali; AJ Oliver; T Samiei; JD Chan; MH Kershaw; CY Slaney

Journal article

Genetic redirection of T cells for the treatment of pancreatic cancer

AI Ali, AJ Oliver, T Samiei, JD Chan, MH Kershaw, CY Slaney

Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2019

DOI: 10.3389/fonc.2019.00056

Open access

Download PDF

Abstract

Conventional treatments for pancreatic cancer are largely ineffective, and the prognosis for the vast majority of patients is poor. Clearly, new treatment options are desperately needed. Immunotherapy offers hope for the development of treatments for pancreatic cancer. A central requirement for the efficacy of this approach is the existence of cancer antigen-specific T cells, but these are often not present or difficult to isolate for most pancreatic tumors. Nevertheless, specific T cells can be generated using genetic modification to express chimeric antigen receptors (CAR), which can enable T cell responses against pancreatic tumor cells. CAR T cells can be produced ex vivo and expanded in..

View full abstract

University of Melbourne Researchers

Clare Slaney Author

Related Projects (5)

BREAST CANCER THERAPY USING DUAL-SPECIFIC T CELLS

ADOPTIVE CELL TRANSFER INCORPORATING VACCINATION (ACTIV) THERAPY FOR CANCER

We have made a breakthrough in a new treatment for cancer that can destroy large tumours in mice. The treatment involves a transfusion of wh..

TARGETING BREAST CANCER USING ADOPTIVE CELL TRANSFER INCORPORATING VACCINATION

Chimeric antigen receptor (CAR) T cell therapy is a novel form of adoptive cellular therapy and has recently generated remarkable effects in..

IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

USING LESSONS FROM TOXIC SHOCK SYNDROME TO ENHANCE BREAST CANCER IMMUNOTHERAPY

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by grants from the Peter MacCallum Cancer Center Foundation, the National Health and Medical Research Council (NHMRC) of Australia (1103352 and 1132373), the National Breast Cancer Foundation (NBCF) of Australia (IIRS-18-064) and Susan G. Komen Breast Cancer Foundation (16376637). CS was supported by a Fellowship from the NBCF. AA was supported by a University of Melbourne International Research scholarship, AO by an Australian Postgraduate Award.